Project

siloa

Keywords

Solution for Digital Early Detection of Alzheimer’s Disease

Project

Worldwide, at least 50 million people are believed to be living with dementia; a number projected to reach 82 million in 2030 and 152 million in 2050. Dementia is a syndrome associated with deterioration of memory, thinking, behaviour, and the ability to perform everyday activities. Early detection and lifestyle interventions are believed to improve quality of life.

Team siloa is working on a digital test for the early detection of Alzheimer’s disease to intervene in the disease progression. For the test, the team is developing a digital biomarker, combining software-based tests that engage brain areas known to be affected in very early stages of Alzheimer’s disease.

Herlind Megges
Herlind Megges
(Charité)

Project Lead

Silka Dawn Freiesleben
Silka Dawn Freiesleben
(Charité)

Project Lead

The test will be initiated by a physician and then conducted by the patients in the comfort of their homes for 15 minutes per day over the span of a month. An Alzheimer’s probability score will then be transferred directly to the physician to maximize certainty for their patients and their caregivers. Siloa wants to enable a future where early detection of Alzheimer’s disease facilitates the diagnostic process and ensures that everybody receives the care they need as early as possible.

Team siloa consists of clinicians and researchers in geriatric medicine at the Memory Clinic at Charité. The team is working with experts in user research, software development, and reimbursement.